Lumateperone, 10 mM in DMSO

Product Description

Biological activity
Lumateperonetosylate(ITI-007tosylate) is a 5-HT2A receptor Chemicalbook antagonist (KI=0.54nM), a partial agonist of the presynaptic D2 receptor and an antagonist of the postsynaptic D2 receptor (KI=32nM).

ITI-722;Lumateperone;ITI-722lumateperone;1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one;313368-91-1Lumateperone(ITI-007);1-Butanone,1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pChemicalbookyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-;1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one;1-(4-Fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone
 

**Applications:**
Lumateperone bears the chemical name: 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone. Lumateperone and its related compounds serve as 5-HT2 receptor agonists and antagonists, utilized in the treatment of central nervous system disorders-specifically those associated with the modulation of 5-HT2C or 5-HT2A receptors. **Indications:** Lumateperone (marketed under the trade name Caplyta) is a first-in-class, multi-targeted agent that exerts multiple pharmacological actions, functioning as a 5-HT2A receptor antagonist, a D2 receptor antagonist, and a serotonin transporter inhibitor. Developed by Intra-Cellular Therapies and subsequently licensed to Bristol-Myers Squibb, the drug was approved by the U.S. Food and Drug Administration (USFDA) for the once-daily oral treatment of schizophrenia in adults.

Packing:

foil bag for 1kg  

1. Or 25KG/drum,or according to your requirement.